

**UK Travel Vaccine Market Forecast to 2028 - COVID-19 Impact and Country Analysis  
By Product (Hepatitis A, Hepatitis B, Meningococcal Vaccines, and Others) and  
Application (Domestic Travel, and Outbound Travel)**

Market Report | 2022-07-15 | 122 pages | The Insight Partners

**AVAILABLE LICENSES:**

- Single User Price \$3000.00
- Site Price \$4000.00
- Enterprise Price \$5000.00

**Report description:**

The travel vaccine market is expected to grow from US\$ 267.56 million in 2021 to US\$ 524.88 million by 2028; it is estimated to grow at a CAGR of 10.1% from 2022 to 2028.

Travel vaccines, also called travel immunizations, are shots travelers get before visiting certain areas of the world that help protect them from developing serious illnesses. Vaccinations work by exposing the body to a weakened/dead germ or part of a germ of the disease. These vaccines are recommended to protect against diseases endemic to the country of origin or destination. It is intended to protect travelers and prevent disease spread within or between countries. In many cases, countries require proof of vaccination for travelers wishing to enter or exit the country.

Travelling and tourism have become an integral part of the human lifestyle. It has added a change in the ongoing routine of people and offered several opportunities to explore different cultures, traditions, spiritualism, rural and ethnic tourism, and wellness and health holidays worldwide. Travelling outside the country requires immunization as a safety and precautionary measure to avoid spreading infections. Various countries have policies to protect their citizens from travel-associated infections. For instance, in the UK, National Health Service (NHS) organizes routine immunization or vaccination schedule for its citizens. If a person travels outside the UK, they must get vaccinated to prevent infectious diseases such as hepatitis A, typhoid, and yellow fever. With ~40 million visitors in 2017, the UK is among the most well-liked foreign travel destinations. Although the UK is renowned for its unpredictable weather, the winters and summers are generally temperate, albeit occasionally damp. The UK recognizes Covaxin as a reliable COVID-19 travel vaccination. This indicates that those immunized with Covaxin, one of the two main COVID-19 vaccines, will not have to separate themselves once they arrive in England. After experiencing a significant annual decline in 2020 due to the COVID-19 pandemic, Statista reports that the number of foreign tourists arriving in Europe increased by

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

~20% in 2021 compared to 2020.

Based on product, the UK travel vaccines market is segmented into hepatitis A, hepatitis B, meningococcal vaccines, and others. The others segment holds the largest market share in 2021. However, the meningococcal vaccines segment is expected to register the highest CAGR during the forecast period. The others segment primarily consists of the human papillomavirus vaccine, Zika virus vaccine, DPT (tetanus/diphtheria/pertussis), yellow fever, typhoid, Japanese encephalitis, measles, mumps and rubella, rabies, polio, influenza, varicella and shingles, cholera, and others. Typhoid is caused by *Salmonella typhi* and is common UK, 21.5 million cases are registered every year with 216,500 deaths every year. Influenza is a common viral infection in Europe, influenza activity appeared to decrease. Influenza A(H3N2) predominated. Cause by *Vibrio cholerae*, cholera is an acute diarrheal illness which affects 1.3 to 4 million people and causes 21,000-143,000 deaths every year UK. Vaccines protect against the HPV group of more than 200 related viruses. Out of these, 200 related viruses more than 40 are spread through direct sexual contact. Two types of HPV can cause genital warts, while more than 24 types can cause certain types of cancers such as, cervical, anal, oropharyngeal, among others. In the US, three HPV vaccines have been licensed for usage - Gardasil, Gardasil 6, and Cervarix. While travel advisories have no recommendations around HPV vaccinations, travelers of all kind prefer getting vaccinated, especially those who travel regularly to regions with high prevalence of HPV.

Based on application, the travel vaccine market is segmented into domestic travel and outbound travel. In 2021, the outbound travel segment is likely to account for the largest share of the market. The market for this segment is expected to grow at the fastest CAGR of 10.4% during 2021-2028. Outbound travel is the act of traveling outside of the home country for leisure, business, or other purposes. Many people travel internationally for business purposes. The number of visits abroad from the UK dropped sharply in 2020 over the previous year due to the COVID-19 pandemic, then fell further in 2021. That year, holidays accounted for the best outbound visits, with roughly 8.9 million trips made for this purpose. However, the number of vacations abroad only accounted for 15% of the holiday trips made in 2019. Overall, the number of visits abroad from the UK was approximately 19 million in 2021. Spending on trips abroad by residents of the UK increased by 12% in 2021 over the previous year, after dropping sharply in 2020 due to the pandemic. Overall, the outbound tourism expenditure within the UK amounted to roughly US\$ 20.7 billion in 2021, rising from US\$ 18.73 billion in 2020 but remaining way below pre-pandemic levels. While the outbound expenditure slightly recovered in 2021, the number of visits abroad from the UK declined further compared to the first year of the crisis. In 2022, in a Travel Leaders Group survey, 24% of Americans stated they planned to travel to Europe. Additionally, it is expected that the tourist arrivals are expected to increase steadily in regions such as Asia and Europe.

A few key primary and secondary sources referred to while preparing the report on the travel vaccine market are the World Health Organization (WHO), UK Health Security Agency, and the CDC.

□

## **Table of Contents:**

### TABLE OF CONTENTS

1. Introduction
  - 1.1 Scope of the Study
  - 1.2 The Insight Partners Research Report Guidance
  - 1.3 Market Segmentation
    - 1.3.1 Travel Vaccines Market - By Product
    - 1.3.2 Travel Vaccines Market - By Application
2. Travel Vaccines Market - Key Takeaways
3. Research Methodology
  - 3.1 Coverage
  - 3.2 Secondary Research
  - 3.3 Primary Research
4. Travel Vaccines Market - Market Landscape
  - 4.1 Overview

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 4.2 PEST Analysis
  - 4.2.1 UK - PEST Analysis
- 4.3 Expert Opinion
- 5. UK Travel Vaccine Market - Key Market Dynamics
  - 5.1 Market Drivers
    - 5.1.1 Increasing Travel and Tourism
    - 5.1.2 Growing Incidences of Infectious Diseases
  - 5.2 Market Restraints
    - 5.2.1 High Cost of Travel Vaccines
  - 5.3 Market Opportunities
    - 5.3.1 Awareness Regarding Vaccines
  - 5.4 Future Trends
    - 5.4.1 Never-ending Demand for Vaccines
  - 5.5 Impact Analysis
- 6. Travel Vaccines Market - UK Analysis
  - 6.1 UK Travel Vaccines Market Revenue Forecast and Analysis
  - 6.2 UK Travel Vaccines Market - Forecast and Analysis
  - 6.3 Market Positioning of Key Players
  - 6.4 Comparative Company Analysis
  - 6.5 Growth Strategy Analysis
  - 6.6 Performance of Key Players
    - 6.6.1 GlaxoSmithKline
    - 6.6.2 Sanofi
- 7. UK Travel Vaccine Market Revenue and Forecasts To 2028 - Product
  - 7.1 Overview
  - 7.2 Travel Vaccines Market Revenue Share, by Product (2021 and 2028)
  - 7.3 Hepatitis A
    - 7.3.1 Overview
    - 7.3.2 Hepatitis A: Travel Vaccines Market- Revenue and Forecast to 2028 (US\$ Million)
  - 7.4 Hepatitis B
    - 7.4.1 Overview
    - 7.4.2 Hepatitis B: Travel Vaccines Market- Revenue and Forecast to 2028 (US\$ Million)
  - 7.5 Meningococcal Vaccines
    - 7.5.1 Overview
    - 7.5.2 Meningococcal Vaccines: Travel Vaccines Market- Revenue and Forecast to 2028 (US\$ Million)
  - 7.6 Others
    - 7.6.1 Overview
    - 7.6.2 Others: Travel Vaccines Market- Revenue and Forecast to 2028 (US\$ Million)
- 8. UK Travel Vaccine Market Revenue and Forecasts To 2028 - Application
  - 8.1 Overview
  - 8.2 Travel Vaccines Market Revenue Share, by Application (2021 and 2028)
  - 8.3 Domestic Travel
    - 8.3.1 Overview
    - 8.3.2 Domestic Travel: Travel Vaccines Market- Revenue and Forecast to 2028 (US\$ Million)
  - 8.4 Outbound Travel
    - 8.4.1 Overview
    - 8.4.2 Outbound Travel: Travel Vaccines Market- Revenue and Forecast to 2028 (US\$ Million)

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9. Travel Vaccines Market Analysis - By Country
  - 9.1 UK: Travel Vaccines Market - Revenue and Forecast to 2028 (US\$ Million)
    - 9.1.1 UK: Travel Vaccines Market - Revenue and Forecast to 2028 (US\$ Million)
    - 9.1.2 UK: Travel Vaccines Market, by Product, 2019-2028 (US\$ Million)
    - 9.1.3 UK: Travel Vaccines Market, by Application, 2019-2028 (US\$ Million)
- 10. Impact Of COVID-19 Pandemic on UK Travel Vaccine Market
  - 10.1 UK: Impact Assessment of COVID-19 Pandemic
- 11. UK Travel Vaccine Market-Industry Landscape
  - 11.1 Overview
  - 11.2 Growth Strategies in the Travel Vaccines Market, (%)
  - 11.3 Organic Developments
    - 11.3.1 Overview
  - 11.4 Inorganic Developments
    - 11.4.1 Overview
- 12. Company Profiles
  - 12.1 GlaxoSmithKline plc.
    - 12.1.1 Key Facts
    - 12.1.2 Business Description
    - 12.1.3 Products and Services
    - 12.1.4 Financial Overview
    - 12.1.5 SWOT Analysis
    - 12.1.6 Key Developments
  - 12.2 Merck & Co., Inc.
    - 12.2.1 Key Facts
    - 12.2.2 Business Description
    - 12.2.3 Products and Services
    - 12.2.4 Financial Overview
    - 12.2.5 SWOT Analysis
    - 12.2.6 Key Developments
  - 12.3 Sanofi
    - 12.3.1 Key Facts
    - 12.3.2 Business Description
    - 12.3.3 Products and Services
    - 12.3.4 Financial Overview
    - 12.3.5 SWOT Analysis
    - 12.3.6 Key Developments
  - 12.4 Novartis AG
    - 12.4.1 Key Facts
    - 12.4.2 Business Description
    - 12.4.3 Products and Services
    - 12.4.4 Financial Overview
    - 12.4.5 SWOT Analysis
    - 12.4.6 Key Developments
  - 12.5 Pfizer Inc.
    - 12.5.1 Key Facts
    - 12.5.2 Business Description
    - 12.5.3 Products and Services

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
- 12.6 Dynavax Technologies
  - 12.6.1 Key Facts
  - 12.6.2 Business Description
  - 12.6.3 Products and Services
  - 12.6.4 Financial Overview
  - 12.6.5 SWOT Analysis
  - 12.6.6 Key Developments
- 12.7 Emergent BioSolutions Inc.
  - 12.7.1 Key Facts
  - 12.7.2 Business Description
  - 12.7.3 Products and Services
  - 12.7.4 Financial Overview
  - 12.7.5 SWOT Analysis
  - 12.7.6 Key Developments
- 12.8 Abbott
  - 12.8.1 Key Facts
  - 12.8.2 Business Description
  - 12.8.3 Products and Services
  - 12.8.4 Financial Overview
  - 12.8.5 SWOT Analysis
  - 12.8.6 Key Developments
- 12.9 Valneva SE.
  - 12.9.1 Key Facts
  - 12.9.2 Business Description
  - 12.9.3 Products and Services
  - 12.9.4 Financial Overview
  - 12.9.5 SWOT Analysis
  - 12.9.6 Key Developments
- 12.10 SEQIRUS
  - 12.10.1 Key Facts
  - 12.10.2 Business Description
  - 12.10.3 Products and Services
  - 12.10.4 Financial Overview
  - 12.10.5 SWOT Analysis
  - 12.10.6 Key Developments
- 13. Appendix
  - 13.1 About The Insight Partners
  - 13.2 Glossary of Terms

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

**UK Travel Vaccine Market Forecast to 2028 - COVID-19 Impact and Country Analysis  
By Product (Hepatitis A, Hepatitis B, Meningococcal Vaccines, and Others) and  
Application (Domestic Travel, and Outbound Travel)**

Market Report | 2022-07-15 | 122 pages | The Insight Partners

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

**ORDER FORM:**

Select license	License	Price
	Single User Price	\$3000.00
	Site Price	\$4000.00
	Enterprise Price	\$5000.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-10"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Signature

An empty rectangular box with a thin black border, intended for a signature.